Alexion Pharma's most recent trend suggests a bullish bias. One trading opportunity on Alexion Pharma is a Bull Put Spread using a strike $150.00 short put and a strike $145.00 long put offers a potential 5.26% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $150.00 by expiration. The full premium credit of $0.25 would be kept by the premium seller. The risk of $4.75 would be incurred if the stock dropped below the $145.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Alexion Pharma is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Alexion Pharma is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Alexion Pharma
SHAREHOLDER ALERT: WeissLaw LLP Reminds TCF and ALXN Shareholders About Its Ongoing Investigations
Tue, 22 Dec 2020 00:56:00 +0000
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:
Alexion Pharmaceuticals, Inc.'s (NASDAQ:ALXN) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Mon, 21 Dec 2020 08:40:39 +0000
Alexion Pharmaceuticals (NASDAQ:ALXN) has had a great run on the share market with its stock up by a significant 40…
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies – ALXN, ELY, CLCT, CBLI
Sat, 19 Dec 2020 19:15:00 +0000
NEW YORK, NY / ACCESSWIRE / December 19, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Alexion Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Alexion Pharmaceuticals, Inc. – ALXN
Sat, 19 Dec 2020 02:00:00 +0000
Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (ALXN) relating to its proposed acquisition by AstraZeneca, PLC. Under the terms of the agreement, Alexion shareholders will receive 2.1243 shares of AstraZeneca and $60.00 in cash per share.
ALEXION INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alexion Pharmaceuticals, Inc. – ALXN
Thu, 17 Dec 2020 00:45:00 +0000
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Alexion Pharmaceuticals, Inc. (NasdaqGS: ALXN) to AstraZeneca PLC (NasdaqGS: AZN). Under the terms of the proposed transaction, shareholders of Alexion will receive only $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca for each share of Alexion that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Related Posts
Also on Market Tamer…
Follow Us on Facebook